Abstract
Neutrophils are the most abundant type of white blood cells in the circulation, protecting the body against pathogens and responding early to inflammation. Although we understand how neutrophils respond to individual stimuli, we know less about how they prioritize between competing signals or respond to combinational signals. This situation is due in part to the lack of adequate experimental systems to provide signals in controlled spatial and temporal fashion. To address these limitations, we designed a platform for generating on-demand, competing chemical gradients and for monitoring neutrophil migration. On this platform, we implemented forty-eight assays generating independent gradients and employed synchronized valves to control the timing of these gradients. We observed faster activation of neutrophils in response to fMLP than to LTB4 and unveiled for the first time a potentiating effect for fMLP during migration towards LTB4. Our observations, enabled by the new tools, challenge the current paradigm of inhibitory competition between distinct chemoattractant gradients and suggest that human neutrophils are capable of complex integration of chemical signals in their environment.
1. Introduction
Neutrophils are the predominant immune cells in circulation. They protect the body against invading pathogens by migrating from the circulation to tissues, following a hierarchy of chemotactic signals that guide their recruitment to the sites of injury.1–3 Their ability to prioritize one chemoattractant over another is important to efficiently navigate the complex tissues.4–6 Particularly, two signalling pathways for neutrophil chemotaxis have been demonstrated that involve phosphatidylinositol-3-OH kinase (PI(3)K) phosphatase and p38 mitogen-activated protein kinase.7–10 The activation of the PI(3)K pathway is triggered by tissue-derived chemokines, i.e. leukotriene B4 (LTB4) and interleukin 8 (IL8) secreted by endothelial cells, macrophages, and mast cells. The activation of the p38 pathway is triggered by bacteria-derived chemokines, i.e. N-formyl-methionyl-leucyl-phenalanine (fMLP) or complement factor 5a (C5a),8–11 and can override signalling through the PI(3)K pathway.
In the past few years, significant progress has been made towards a better understanding of how neutrophils respond to competing signals.12–15 However, a precise quantification of the responses to temporal sequences of stimuli has not been studied. This is mainly due to the difficulty of extracting the role of individual chemokines at each stage during an immune system response in vivo and the lack of adequate in vitro assays capable of providing complex chemoattractant signals in a controlled and temporal fashion. One of the common platforms for studying human leukocytes trafficking in vitro is the transwell filter assay that provides an end-point count of migrating cells towards a single chemoattractant.16 Microfluidic-based platforms, on the other hand, have provided researchers with valuable tools to precisely quantify the full response of leukocytes to stable chemoattractant gradients on a single-cell resolution.17 The tree-shaped single gradient generator was among the first of these platforms.18,19 Other microfluidic devices were designed to generate overlapping gradients from multiple sources.20–22 Pneumatic valves and light-induced methods allowed for the generation of spatiotemporal switchable gradients.23,24 Simpler platforms also emerged without the need for fluidic pumps.25–27 Of those, gel-based platforms separated cellular and chemokine compartments,28,29 surface-tension based platforms were implemented in a dense array format to create a high-throughput chemotaxis assay,30–32 and a multi-layered platform provided week-long lasting gradients.33 However, none of the existing platforms can provide spatial-temporal and simultaneous gradients in a large-scale manner for systematic studies of neutrophil chemotaxis extracted from a single experiment and requiring a single blood processing procedure.
Here, we designed a chemotaxis platform capable of exposing neutrophils to 48 unique combinations of dual chemoattractant gradients. We employed the platform to test human neutrophil responses in the presence of simultaneous but spatially opposite chemoattractant gradients. We observed that human neutrophils could prioritize their responses toward fMLP over LTB4 chemoattractants and found that response time can be accelerated in the presence of chemoattractant combinations. These observations challenge the current paradigm of down-regulating interactions between chemokine signalling pathways.7 Our observations suggest that in certain situations, synergistic effects are possible between different chemokine gradients, suggesting more sophisticated interplay can be taking place between chemokine signalling pathways in neutrophils.
2. Materials and methods
2.1 Microfluidic platform fabrication
The fabrication was performed using standard soft lithographic techniques on two six-inch wafers (Fig. 1A). Multiple layers of photoresist (SU8, Microchem, Newton, MA, USA) were aligned on the network wafer, with thicknesses of 5 μm for neutrophil migration channels, 10 μm for the entrance zone to the migration channels, 50 μm for sinks and all compartments on the network wafer. A single layer of 50 μm in thickness was patterned for pneumatic chambers on the valve control wafer.
A mixture of PDMS (Polydimethylsiloxane) and its curing agent (SYLGARD 184 A/B, Dow Corning, Midland, MI, USA) at 10:1 was spun to a thickness of 150 μm and baked in an oven set to 65 °C for at least 3 hours. For the control layer, the mixture was poured to a thickness of ~3 mm and cured at room temperature for 48 hours to avoid the shrinkage of PDMS and dimensional mismatch with the network layer (Fig. 1B). Afterwards, the control layer was peeled off and punched with a 1.5 mm puncher (Harris Uni-Core, Ted Pella Inc., Reading, CA, USA) to define two control lines for side and central valves. The network and control layers were then treated with oxygen plasma for bonding. A volume of 1 mL of high purity ethanol (99.9%, Sigma-Aldrich, St. Louis, MO, USA) was gently spread on the top of the network layer to act as a surfactant.34 The control layer was then placed and aligned to the network layer (Fig. 1C). After removal of excess ethanol by suction, the two aligned layers were transferred back to the oven and left to bake overnight, cut, gently peeled off, and punched with a 1.2 mm puncher. The assembled PDMS layers were treated with oxygen plasma at 50 mW, 10 ccm, for 35 seconds (PX-250, March Plasma Systems, Petersburg, FL, USA) for irreversible bonding to a glass-bottomed UniWell plate (MGB001-1-2-LG, Matrical Bioscience, Spokane, WA, USA).
To avoid the collapse and permanent bonding of the ‘default-closed’ valves to the glass substrate, a special protocol was employed during the bonding of the assembled PDMS layers. First, the ‘default-closed’ side valves were kept elevated off the glass surface in an open position by applying negative pressure around –27 psi during a 15 minute bonding step when the plasma-treated surfaces remained active. Afterwards, the valves were closed and opened fast and repeatedly, to deactivate plasma-activated surfaces by touching and separating them before bonding can occur, and to ensure full functionality of the valves (Fig. 1D). Finally, the platforms were immediately primed for 30 minutes with a solution of human-fibronectin (Sigma-Aldrich), diluted to 100 nM in distilled water that had been autoclaved and filtered (0.2 μm filter, AM9920, Life Technologies, Grand Island, NY, USA). Fibronectin-treated surfaces were then rinsed with sterile water and the platform was filled with cell culture medium (Iscove's Modified Dulbecco's Medium) supplemented with 10% FBS (Sigma-Aldrich) and 1% penicillin/streptomycin (Life Technologies).
2.2 Cell preparation
De-identified, fresh human blood samples from healthy volunteers, aged 18 years and older, were purchased from Research Blood Components (Alston, MA). Peripheral blood was drawn in heparinized-tubes (Vacutainer; Becton Dickinson) and human neutrophils were isolated within 2 hours after blood collection using HetaSep followed by the EasySep Human Neutrophil Enrichment Kits (STEMCELL Technologies, Vancouver, Canada). After isolation, cells were washed using cell culture medium without serum. The cell membrane was stained with red fluorescent dye (PKH26PCL, Sigma-Aldrich). The stained neutrophils were re-suspended in medium at a density of 20 × 106 cells mL–1. Ten μL of cell suspension were injected into the cell compartment and incubated at 37 °C supplied with 5% CO2 for 30 minutes. Afterwards, 10 μL of each chemokine solution was injected into its designated chemokine compartment.
2.3 Time-lapse imaging
To simultaneously image the moving neutrophils in the arrayed 48 platforms, we used an automated microscope equipped with a motorized stage in the x and y directions (EclipseTi, Micro Video Instruments, Avon, MA, USA). A perfect focusing system (PFS, Nikon) compensated for any mechanical disturbance in the z direction and maintained the quality of focusing through the experiment. For live-cell imaging, we integrated the microscope with a heated incubating stage (LiveCell 05-11-0032 Rev B, Pathology Devices Inc., Westminster, MD, USA), which was set at 37.7 °C, 5% CO2, and 85% humidity. We imaged the cells every 3 minutes using phase contrast and fluorescence for 2 hours with a 4× objective lens and in a large-area mode of 2 × 2 mm2 with a 15% stitching.
2.4 Analysis of cellular motility
Image analysis of the time-lapse movies at each location was performed using the NIS Elements (Nikon Inc., Melville, NY, USA) and automated using the open-sourced software, CellProfiler (Broad Institute, Boston, MA, USA). The analysis was limited to the first hour of experiments, when the slope of chemical gradients maintained about 80% of the initial slope, at the start of the experiments. Also, we restricted the analysis to the neutrophils inside the migration channels and measured migration and neutrophil response time in the x direction along the migration channels. We defined the neutrophil “response time” as the time for resting neutrophils to fully attach to the fibronectin-coated glass surface and migrate at least 150 μm (70 μm in the entrance region and 80 μm inside the channel). Raw data was processed and analyzed using MATLAB (MathWorks, Inc, Natick, MA).
3. Results and discussion
3.1 Design of chemotaxis platform providing on-demand, simultaneous gradients, and on-chip validation
To study neutrophil responses to various combinations of gradients in complex immune environments, we designed a microfluidic platform that provides precise spatial and temporal control of chemokine gradients, and confines neutrophils in small channels during chemotaxis. The platform has a cellular compartment in the center (cell, Fig. 2), two chemokine chambers of 50 nL in volume, and two chemokine compartments on the sides (CK1 and CK2, Fig. 2). Two arrays of migration channels (5 × 10 × 500 μm3 in height, width, and length) connect the chemokine chambers and the central compartment. The platform contains two types of pneumatic valves to generate two distinct gradients of chemokines and apply these to cells at the same time (Fig. 2A). Two ‘default-closed’ valves are placed between chemokine compartments and chemokine chambers and are opened temporarily during chemokine priming of the chambers and migration channels (Fig. 2B, D 1–2).35 One ‘default-open’ central valve is closed during cell loading and chemokine priming, and when it opens, cells are immediately exposed to gradients and start chemotaxis (Fig. 2C, D 3–4). In order to generate similar gradients of the two chemoattractants having different molecular weights, we designed two sinks between the migration channels and the central compartment to compensate for the difference in diffusivity of the two chemokines during the priming step. These sinks are twenty times larger in volume than the migration channels. For valve operation, a positive pressure (PP), approximately 30 psi relative to ambient pressure, was used to close the ‘default-open’ valves and a negative pressure (NP), approximately –27 psi, to open ‘default-closed’ valves. All 48 pairs of valves on the platform are controlled by only two pneumatic lines, enabling the synchronized operation of forty-eight independent platforms.
3.2 Validation of the spatial and temporal chemokine gradients
We visualized the formation of chemical gradients inside the devices using fluorescent dyes. To account for the differences in molecular weight among different chemokines, we tested fluorescein sodium salt (molecular weight 376 Da) and various FITC-conjugated dextrans (between 3 kDa and 70 kDa Fig. 3). The process started with priming the channels by opening the side valves and filling the side compartments and migration channels with chemokine (Fig. 3A). The concentration of FITC-dextran in the chemokine compartment and channels stabilized in between 2 minutes for fluorescein of 376 Da, and 18 minutes for the 70 kDa dextran (Fig. 3B–D). During the priming period, no leakage of fluorescein or fluorescently labelled dextran inside the central compartment was observed. Later, the central valve was opened to form a stable gradient along the channels, between the central and side compartments (Fig. 3E). Gradients of fluorescein and FITC-dextran of 3 kDa stabilized within 3 minutes along the migration channels (Fig. 3F, G) and the central compartment (Fig. 3H). For larger molecular weight dyes (10, 40 and 70 kDa), gradients stabilized within 10 minutes after opening the central valve. The gradients along the migration channels remained at least 80% of their original slope during the first hour. The duration of the stable gradients, validated by dye experiments, provided the effective period of the platform for chemotaxis measurements.
3.3 Quantification of directional migration in response to competing gradients
To probe the response of neutrophils to two simultaneous chemoattractant gradients, we introduced fMLP and LTB4 to the side compartments and introduced neutrophils to the central compartment. The two chemokines stimulate cell migration through distinct pathways that involve PI(3)K and p38 MAPK, respectively.7 After opening the central valve, we observed a higher number of neutrophils migrating toward the source of fMLP at 100 nM compared to LTB4 at 100 nM (Fig. 4A, ESI† movie 1). This bias was consistent with previously reported data7–10 suggesting a hierarchy in which end-point chemoattractants (fMLP) override intermediate-range chemoattractants (LTB4). The lower priority towards LTB4 was evident from the delay to initiate persistent migration when compared to the higher-priority response toward fMLP. For systematic comparison, all conditions were tested in a single run with neutrophils from the same donor and each condition was repeated three times.
The “response time” as defined in this work is different from the “activation time” previously reported7 in that it includes, in addition to the time for cells to initiate migration along the gradient, the time to fully establish directional migration in migration channels. This definition was used to avoid the noisy and random changes in speed and directionality of neutrophils randomly distributed in the central compartment and take advantage of the consistent measurement inside confined channels.
The response times to the two chemokines were different. It took 27.0 ± 5.3 min to establish fully developed directional migration toward 10 nM fMLP gradient, compared to 34.0 ± 5.7 min toward 100 nM LTB4 (Fig. 4B). The first neutrophils migrated through the channels and reached the fMLP chamber 36 minutes after the central valve was opened, compared with 51 minutes for the LTB4. More neutrophils accumulated in the side chambers in response to fMLP compared to LTB4 and the accumulation continued for more than 2 hours (Fig. 4C).
The migration speed to various concentrations of chemokines, showed similar profiles for fMLP and LTB4, with a peak speed of 13.6 ± 0.7 μm min–1 at 10 nM of fMLP alone (Fig. 4D), consistent with the average migration speed previously reported in other studies.10 The response time decreased with increasing concentrations of chemokines, and was systematically shorter for fMLP compared to LTB4 at similar concentrations (Fig. 4E). These differences in response times cannot be accounted for by the differences in diffusion coefficient between of the two chemokines, which have very similar molecular weights (fMLP: 438 Da and LTB4: 338 Da). Moreover, the time for either chemokine to cross the central compartment was much shorter than cellular response time. Therefore, the observed differences in response time towards the two chemokines are intrinsic to neutrophils. Additional evidence was provided by imaging the faster attachment of human neutrophils to the glass bottom of the central chamber and polarization in the presence of fMLP compared to LTB4 (ESI† Fig. S1). Specifically, we observed that neutrophils fully attached to the glass substrate and polarized within 10 minutes after loading in the presence of uniform fMLP at 100 nM. On the other hand, neutrophils did not adhere fully or were still round at 10 minutes in the presence of uniform LTB4 at 100 nM or no chemokine, respectively. Therefore, faster attachment and polarization are the likely explanations for the shorter response time in the presence of fMLP compared to LTB4.
The two chemoattractants used in this study, LTB4 and fMLP, have comparable molecular weight with the fluorescein sodium salt used during platform validation. Thus, it is expected for their chemokine gradients to evolve similarly in time with the gradients of fluorescein dye. Considering the reported 20% reduction of the fluorescein gradient within the first hour, we estimate that 80% of original gradients of chemokines are still present at one hour. These gradients were effective for directing neutrophil migration for more than 2 hours after the start of the experiment. Therefore, this platform can potentially be used with chemoattractants of larger molecular weight, and the data from the characterization of the device using larger molecular weight FITC-dextran could serve as a guide for these conditions.
3.4 Real-time evaluation of chemotaxis cross-activation
To investigate the response of neutrophils to stimulation by simultaneous gradients of fMLP and LTB4, we measured the speed and response time of neutrophils at various concentrations (Fig. 5). Neutrophil migration speed toward fMLP gradients at 10 nM increased by less than 10% in the presence of LTB4 gradient at 100 nM (from 13.6 ± 0.7 to 15.4 ± 0.7 μm min–1, Fig. 5A). The increase was comparable to that toward the LTB4 gradient at 100 nM in the presence of the fMLP gradient at 10 nM (from 13.3 ± 0.6 to 14.2 ± 0.6 μm min–1 Fig. 5B). The response time for chemotaxis toward fMLP was shortened by 10% in the presence of the LTB4 gradient (from 27.0 ± 5.3 to 23.7 ± 0.8 min, Fig. 5C). Significantly shorter response times were observed for chemotaxis toward LTB4 in the presence of the fMLP gradient (from 34.0 ± 5.7 to 27.0 ± 2.1 min, Fig. 5D). In all of the control conditions, neutrophils did not enter into the migration channels (ESI† Fig. S2).
4. Conclusions
We designed a chemotaxis platform capable of providing up to 48 stable combinations of chemoattractant gradients by the simple operation of two pneumatic lines. We observed a hierarchical neutrophil response to competing gradients and performed precise measurements of the speed and response time. We quantified the dominant effect of the end-point fMLP gradient over an intermediate-range LTB4 chemoattractant gradient. We observed surprisingly shorter chemotactic response times toward LTB4 gradients in the presence of fMLP compared to gradients of only LTB4 or fMLP.
Supplementary Material
Acknowledgements
This work was supported in part by funding from the National Institutes of Health, grants GM092804, DE019938, and EB002503.
Footnotes
Electronic supplementary information (ESI) available. See DOI: 10.1039/c3lc50959a
References
- 1.Liu M, Chen K, Yoshimura T, Liu Y, Gong W, Wang A, Gao J-L, Murphy PM, Wang JM. Sci. Rep. 2012;2:1–7. doi: 10.1038/srep00786. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Mackay CR. Nat. Immunol. 2001;2:95–101. doi: 10.1038/84298. [DOI] [PubMed] [Google Scholar]
- 3.Nathan C. Nature. 2002;420:846–852. doi: 10.1038/nature01320. [DOI] [PubMed] [Google Scholar]
- 4.Arner P. J. Intern. Med. 2007;262:404–407. doi: 10.1111/j.1365-2796.2007.01850.x. [DOI] [PubMed] [Google Scholar]
- 5.Serhan CN, Yacoubian S, Yang R. Annu. Rev. Pathol.: Mech. Dis. 2008;3:279–312. doi: 10.1146/annurev.pathmechdis.3.121806.151409. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CCM, Beck PL, Muruve DA, Kubes P. Science. 2010;330:362–366. doi: 10.1126/science.1195491. [DOI] [PubMed] [Google Scholar]
- 7.Heit B, Robbins SM, Downey CM, Guan Z, Colarusso P, Miller BJ, Jirik FR, Kubes P. Nat. Immunol. 2008;9:743–752. doi: 10.1038/ni.1623. [DOI] [PubMed] [Google Scholar]
- 8.Irimia D. Annu. Rev. Biomed. Eng. 2010;12:259–284. doi: 10.1146/annurev-bioeng-070909-105241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Foxman EF, Kunkel EJ, Butcher EC. J. Cell Biol. 1999;147:577–588. doi: 10.1083/jcb.147.3.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kim D, Haynes CL. Anal. Chem. 2012;84:6070–6078. doi: 10.1021/ac3009548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Heit B, Liu L, Colarusso P, Puri KD, Kubes P. J. Cell Sci. 2008;121:205–214. doi: 10.1242/jcs.020412. [DOI] [PubMed] [Google Scholar]
- 12.Foxman EF, Campbell JJ, Butcher EC. J. Cell Biol. 1997;139:1349–1360. doi: 10.1083/jcb.139.5.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Funamoto S, Meili R, Lee S, Parry L, Firtel RA. Cell. 2002;109:611–623. doi: 10.1016/s0092-8674(02)00755-9. [DOI] [PubMed] [Google Scholar]
- 14.Quinton LJ. Am. J. Physiol. 2004;286:465L–472. [Google Scholar]
- 15.Liu X, Ma B, Malik AB, Tang H, Yang T, Sun B, Wang G, Minshall RD, Li Y, Zhao Y, Ye RD, Xu J. Nat. Immunol. 2012;13:457–464. doi: 10.1038/ni.2258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Boyden S. J. Exp. Med. 1962;115:453–466. doi: 10.1084/jem.115.3.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Wu J, Wu X, Lin F. Lab Chip. 2013;13:2484–2499. doi: 10.1039/c3lc50415h. [DOI] [PubMed] [Google Scholar]
- 18.Jeon NL, Dertinger SKW, Chiu DT, Choi IS, Stroock AD, Whitesides GM. Langmuir. 2000;16:8311–8316. [Google Scholar]
- 19.Li Jeon N, Baskaran H, Dertinger SKW, Whitesides GM, Van de Water L, Toner M. Nat. Biotechnol. 2002;20:826–830. doi: 10.1038/nbt712. [DOI] [PubMed] [Google Scholar]
- 20.Atencia J, Morrow J, Locascio LE. Lab Chip. 2009;9:2707–2714. doi: 10.1039/b902113b. [DOI] [PubMed] [Google Scholar]
- 21.Choi E, Chang H-K, Young Lim C, Kim T, Park J. Lab Chip. 2012;12:3968–3975. doi: 10.1039/c2lc40450h. [DOI] [PubMed] [Google Scholar]
- 22.Qasaimeh MA, Gervais T, Juncker D. Nat. Commun. 2011;2:464. doi: 10.1038/ncomms1471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Irimia D, Liu S-Y, Tharp WG, Samadani A, Toner M, Poznansky MC. Lab Chip. 2006;6:191–198. doi: 10.1039/b511877h. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Beta C, Wyatt D, Rappel W-J, Bodenschatz E. Anal. Chem. 2007;79:3940–3944. doi: 10.1021/ac070033y. [DOI] [PubMed] [Google Scholar]
- 25.Gao Y, Sun J, Lin W-H, Webb DJ, Li D. Microfluid. Nanofluid. 2011;12:887–895. doi: 10.1007/s10404-011-0908-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Buxboim A, Geron E, Alon R, Bar-Ziv R. Small. 2009;5:1723–1726. doi: 10.1002/smll.200900042. [DOI] [PubMed] [Google Scholar]
- 27.Butler KL, Ambravaneswaran V, Agrawal N, Bilodeau M, Toner M, Tompkins RG, Fagan S, Irimia D. PLoS One. 2010;5:e11921. doi: 10.1371/journal.pone.0011921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kim M, Kim T. Anal. Chem. 2010;82:9401–9409. doi: 10.1021/ac102022q. [DOI] [PubMed] [Google Scholar]
- 29.Zhu X, Si G, Deng N, Ouyang Q, Wu T, He Z, Jiang L, Luo C, Tu Y. Phys. Rev. Lett. 2012;108:128101. doi: 10.1103/PhysRevLett.108.128101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Berthier E, Surfus J, Verbsky J, Huttenlocher A, Beebe D. Integr. Biol. 2010;2:630–638. doi: 10.1039/c0ib00030b. [DOI] [PubMed] [Google Scholar]
- 31.Kim E, Schueller O, Sweetnam PM. Lab Chip. 2012;12:2255–2264. doi: 10.1039/c2lc21078a. [DOI] [PubMed] [Google Scholar]
- 32.Hancock MJ, He J, Mano JF, Khademhosseini A. Small. 2011;7:892–901. doi: 10.1002/smll.201002088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Cho H, Hashimoto T, Wong E, Hori Y, Wood LB, Zhao L, Haigis KM, Hyman BT, Irimia D. Sci. Rep. 2013;3:1–7. doi: 10.1038/srep01823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Kim JY, Baek JY, Lee KA, Lee SH. Sens. Actuators, A. 2005;119:593–598. [Google Scholar]
- 35.Devaraju NSGK, Unger MA. Lab Chip. 2012;12:4809–4815. doi: 10.1039/c2lc21155f. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.